bioAffinity Technologies, Inc. (NASDAQ: BIAF) Stock Competitors & Peer Comparison
See BIAF's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BIAF and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIAF | $2.42 | +1.26% | 15.2M | -0.28 | -$8.52 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.65% |
| TMO | $717.71 | -0.07% | 265.9B | 30.99 | $23.16 | +0.26% |
| DHR | $235.31 | -0.34% | 165.5B | 29.49 | $7.98 | +0.65% |
| IDXX | $702.59 | +0.85% | 55.4B | 49.41 | $14.22 | N/A |
| A | $176.95 | -0.52% | 49.9B | 30.45 | $5.81 | +0.57% |
| NTRA | $319.82 | +2.51% | 46.4B | -242.29 | -$1.32 | N/A |
| WAT | $470.90 | -0.97% | 46.2B | 34.41 | $13.68 | N/A |
| IQV | $274.53 | -0.23% | 45.2B | 22.63 | $12.13 | N/A |
| MTD | $1,749.01 | -0.14% | 35B | 40.19 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
BIAF vs DHR-PB Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, BIAF's ROE is -3.31%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, BIAF is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
BIAF vs TMO Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, TMO has a market cap of 265.9B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while TMO trades at $717.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas TMO's P/E ratio is 30.99. In terms of profitability, BIAF's ROE is -3.31%, compared to TMO's ROE of +0.13%. Regarding short-term risk, BIAF is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
BIAF vs DHR Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, DHR has a market cap of 165.5B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while DHR trades at $235.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas DHR's P/E ratio is 29.49. In terms of profitability, BIAF's ROE is -3.31%, compared to DHR's ROE of +0.08%. Regarding short-term risk, BIAF is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
BIAF vs IDXX Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, IDXX has a market cap of 55.4B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while IDXX trades at $702.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas IDXX's P/E ratio is 49.41. In terms of profitability, BIAF's ROE is -3.31%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, BIAF is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
BIAF vs A Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, A has a market cap of 49.9B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while A trades at $176.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas A's P/E ratio is 30.45. In terms of profitability, BIAF's ROE is -3.31%, compared to A's ROE of +0.20%. Regarding short-term risk, BIAF is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check A's competition here
Natera, Inc. (NASDAQ: NTRA)
BIAF vs NTRA Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, NTRA has a market cap of 46.4B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while NTRA trades at $319.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas NTRA's P/E ratio is -242.29. In terms of profitability, BIAF's ROE is -3.31%, compared to NTRA's ROE of -0.09%. Regarding short-term risk, BIAF is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check NTRA's competition here
Waters Corporation (NYSE: WAT)
BIAF vs WAT Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, WAT has a market cap of 46.2B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while WAT trades at $470.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas WAT's P/E ratio is 34.41. In terms of profitability, BIAF's ROE is -3.31%, compared to WAT's ROE of +0.01%. Regarding short-term risk, BIAF is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
BIAF vs IQV Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, IQV has a market cap of 45.2B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while IQV trades at $274.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas IQV's P/E ratio is 22.63. In terms of profitability, BIAF's ROE is -3.31%, compared to IQV's ROE of +0.22%. Regarding short-term risk, BIAF is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check IQV's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
BIAF vs MTD Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, MTD has a market cap of 35B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while MTD trades at $1,749.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas MTD's P/E ratio is 40.19. In terms of profitability, BIAF's ROE is -3.31%, compared to MTD's ROE of +149.66%. Regarding short-term risk, BIAF is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check MTD's competition here
Illumina, Inc. (NASDAQ: ILMN)
BIAF vs ILMN Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, ILMN has a market cap of 32.2B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while ILMN trades at $212.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas ILMN's P/E ratio is 42.33. In terms of profitability, BIAF's ROE is -3.31%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, BIAF is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check ILMN's competition here
Labcorp Holdings Inc. (NYSE: LH)
BIAF vs LH Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, LH has a market cap of 30.2B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while LH trades at $372.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas LH's P/E ratio is 22.10. In terms of profitability, BIAF's ROE is -3.31%, compared to LH's ROE of +0.12%. Regarding short-term risk, BIAF is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
BIAF vs DGX Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, DGX has a market cap of 28.6B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while DGX trades at $258.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas DGX's P/E ratio is 25.51. In terms of profitability, BIAF's ROE is -3.31%, compared to DGX's ROE of +0.15%. Regarding short-term risk, BIAF is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
BIAF vs GH Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, GH has a market cap of 20.9B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while GH trades at $154.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas GH's P/E ratio is -44.35. In terms of profitability, BIAF's ROE is -3.31%, compared to GH's ROE of +2.49%. Regarding short-term risk, BIAF is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
BIAF vs EXAS Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas EXAS's P/E ratio is -95.37. In terms of profitability, BIAF's ROE is -3.31%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, BIAF is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
BIAF vs MEDP Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, MEDP has a market cap of 18.6B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while MEDP trades at $664.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas MEDP's P/E ratio is 36.85. In terms of profitability, BIAF's ROE is -3.31%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, BIAF is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
BIAF vs RVTY Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, RVTY has a market cap of 17.7B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while RVTY trades at $158.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas RVTY's P/E ratio is 29.57. In terms of profitability, BIAF's ROE is -3.31%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, BIAF is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
BIAF vs ILMNV Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas ILMNV's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -3.31%, compared to ILMNV's ROE of N/A. Regarding short-term risk, BIAF is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
BIAF vs CRL Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, CRL has a market cap of 16.4B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while CRL trades at $342.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas CRL's P/E ratio is 34.63. In terms of profitability, BIAF's ROE is -3.31%, compared to CRL's ROE of +0.01%. Regarding short-term risk, BIAF is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
BIAF vs ICLR Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, ICLR has a market cap of 15B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while ICLR trades at $199.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas ICLR's P/E ratio is 16.29. In terms of profitability, BIAF's ROE is -3.31%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, BIAF is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check ICLR's competition here
PerkinElmer, Inc. (NYSE: PKI)
BIAF vs PKI Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas PKI's P/E ratio is 41.45. In terms of profitability, BIAF's ROE is -3.31%, compared to PKI's ROE of +0.04%. Regarding short-term risk, BIAF is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check PKI's competition here
Qiagen N.V. (NYSE: QGEN)
BIAF vs QGEN Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while QGEN trades at $50.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas QGEN's P/E ratio is 20.79. In terms of profitability, BIAF's ROE is -3.31%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, BIAF is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
BIAF vs RDNT Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, RDNT has a market cap of 6.1B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while RDNT trades at $78.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas RDNT's P/E ratio is 169.70. In terms of profitability, BIAF's ROE is -3.31%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, BIAF is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
BIAF vs GRAL Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, GRAL has a market cap of 5.6B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while GRAL trades at $125.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas GRAL's P/E ratio is -12.89. In terms of profitability, BIAF's ROE is -3.31%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, BIAF is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check GRAL's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
BIAF vs BLLN Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, BLLN has a market cap of 5.3B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while BLLN trades at $110.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas BLLN's P/E ratio is 157.47. In terms of profitability, BIAF's ROE is -3.31%, compared to BLLN's ROE of +0.09%. Regarding short-term risk, BIAF is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
BIAF vs SHC Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, SHC has a market cap of 4.7B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while SHC trades at $16.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas SHC's P/E ratio is 17.13. In terms of profitability, BIAF's ROE is -3.31%, compared to SHC's ROE of +0.26%. Regarding short-term risk, BIAF is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
BIAF vs SYNH Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas SYNH's P/E ratio is 61.40. In terms of profitability, BIAF's ROE is -3.31%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, BIAF is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check SYNH's competition here
CareDx, Inc (NASDAQ: CDNA)
BIAF vs CDNA Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, CDNA has a market cap of 4.3B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while CDNA trades at $81.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas CDNA's P/E ratio is 96.63. In terms of profitability, BIAF's ROE is -3.31%, compared to CDNA's ROE of +0.34%. Regarding short-term risk, BIAF is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
BIAF vs OLK Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas OLK's P/E ratio is -96.59. In terms of profitability, BIAF's ROE is -3.31%, compared to OLK's ROE of -0.07%. Regarding short-term risk, BIAF is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
BIAF vs NEO Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while NEO trades at $16.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas NEO's P/E ratio is 129.46. In terms of profitability, BIAF's ROE is -3.31%, compared to NEO's ROE of -0.04%. Regarding short-term risk, BIAF is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check NEO's competition here
Veracyte, Inc. (NASDAQ: VCYT)
BIAF vs VCYT Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, VCYT has a market cap of 2B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while VCYT trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas VCYT's P/E ratio is 12.56. In terms of profitability, BIAF's ROE is -3.31%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, BIAF is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check VCYT's competition here
Personalis, Inc. (NASDAQ: PSNL)
BIAF vs PSNL Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while PSNL trades at $15.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas PSNL's P/E ratio is -14.64. In terms of profitability, BIAF's ROE is -3.31%, compared to PSNL's ROE of -0.50%. Regarding short-term risk, BIAF is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check PSNL's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
BIAF vs WGS Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, WGS has a market cap of 1.6B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while WGS trades at $55.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas WGS's P/E ratio is 152.94. In terms of profitability, BIAF's ROE is -3.31%, compared to WGS's ROE of -0.42%. Regarding short-term risk, BIAF is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check WGS's competition here
OPKO Health, Inc. (NASDAQ: OPK)
BIAF vs OPK Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, OPK has a market cap of 1.3B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while OPK trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas OPK's P/E ratio is -19.00. In terms of profitability, BIAF's ROE is -3.31%, compared to OPK's ROE of -0.12%. Regarding short-term risk, BIAF is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
BIAF vs CSTL Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while CSTL trades at $33.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas CSTL's P/E ratio is -51.50. In terms of profitability, BIAF's ROE is -3.31%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, BIAF is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
BIAF vs FLGT Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, FLGT has a market cap of 718M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while FLGT trades at $25.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas FLGT's P/E ratio is 2570.00. In terms of profitability, BIAF's ROE is -3.31%, compared to FLGT's ROE of -0.09%. Regarding short-term risk, BIAF is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
BIAF vs GRALV Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas GRALV's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -3.31%, compared to GRALV's ROE of N/A. Regarding short-term risk, BIAF is more volatile compared to GRALV. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
BIAF vs MYGN Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, MYGN has a market cap of 548.7M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while MYGN trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas MYGN's P/E ratio is -44.00. In terms of profitability, BIAF's ROE is -3.31%, compared to MYGN's ROE of -0.40%. Regarding short-term risk, BIAF is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
BIAF vs CO Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas CO's P/E ratio is 5.06. In terms of profitability, BIAF's ROE is -3.31%, compared to CO's ROE of +0.11%. Regarding short-term risk, BIAF is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
BIAF vs FLDM Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas FLDM's P/E ratio is -4.74. In terms of profitability, BIAF's ROE is -3.31%, compared to FLDM's ROE of +0.26%. Regarding short-term risk, BIAF is more volatile compared to FLDM. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check FLDM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
BIAF vs GTH Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas GTH's P/E ratio is -1.11. In terms of profitability, BIAF's ROE is -3.31%, compared to GTH's ROE of -1.01%. Regarding short-term risk, BIAF is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check GTH's competition here
Exagen Inc. (NASDAQ: XGN)
BIAF vs XGN Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, XGN has a market cap of 122M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while XGN trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas XGN's P/E ratio is -6.22. In terms of profitability, BIAF's ROE is -3.31%, compared to XGN's ROE of -1.26%. Regarding short-term risk, BIAF is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check XGN's competition here
Genetic Technologies Limited (NASDAQ: GENE)
BIAF vs GENE Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas GENE's P/E ratio is -38.25. In terms of profitability, BIAF's ROE is -3.31%, compared to GENE's ROE of -1.85%. Regarding short-term risk, BIAF is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
BIAF vs FRNM Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, FRNM has a market cap of 94.3M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while FRNM trades at $11.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas FRNM's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -3.31%, compared to FRNM's ROE of N/A. Regarding short-term risk, BIAF is more volatile compared to FRNM. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check FRNM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
BIAF vs BDSX Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, BDSX has a market cap of 82.4M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while BDSX trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas BDSX's P/E ratio is -3.19. In terms of profitability, BIAF's ROE is -3.31%, compared to BDSX's ROE of -4.42%. Regarding short-term risk, BIAF is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check BDSX's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
BIAF vs IMDX Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, IMDX has a market cap of 78.2M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while IMDX trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas IMDX's P/E ratio is -1.60. In terms of profitability, BIAF's ROE is -3.31%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, BIAF is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check IMDX's competition here
Precipio, Inc. (NASDAQ: PRPO)
BIAF vs PRPO Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, PRPO has a market cap of 44.4M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while PRPO trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas PRPO's P/E ratio is -38.15. In terms of profitability, BIAF's ROE is -3.31%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, BIAF is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
BIAF vs AKU Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas AKU's P/E ratio is -0.13. In terms of profitability, BIAF's ROE is -3.31%, compared to AKU's ROE of -5.32%. Regarding short-term risk, BIAF is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
BIAF vs CEMI Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas CEMI's P/E ratio is -0.63. In terms of profitability, BIAF's ROE is -3.31%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, BIAF is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
BIAF vs ENZ Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas ENZ's P/E ratio is -2.24. In terms of profitability, BIAF's ROE is -3.31%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, BIAF is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
BIAF vs PMD Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas PMD's P/E ratio is -5.24. In terms of profitability, BIAF's ROE is -3.31%, compared to PMD's ROE of -0.32%. Regarding short-term risk, BIAF is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
BIAF vs ME Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas ME's P/E ratio is -0.03. In terms of profitability, BIAF's ROE is -3.31%, compared to ME's ROE of -3.47%. Regarding short-term risk, BIAF is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
BIAF vs MYNZ Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, BIAF's ROE is -3.31%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, BIAF is more volatile compared to MYNZ. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
BIAF vs BNR Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, BNR has a market cap of 14.3M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while BNR trades at $13.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas BNR's P/E ratio is -15.57. In terms of profitability, BIAF's ROE is -3.31%, compared to BNR's ROE of -0.13%. Regarding short-term risk, BIAF is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check BNR's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
BIAF vs QUCY Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, QUCY has a market cap of 14.2M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while QUCY trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas QUCY's P/E ratio is -0.03. In terms of profitability, BIAF's ROE is -3.31%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, BIAF is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
BIAF vs MDXH Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, MDXH has a market cap of 14M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while MDXH trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas MDXH's P/E ratio is -0.20. In terms of profitability, BIAF's ROE is -3.31%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, BIAF is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check MDXH's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
BIAF vs CHEK Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas CHEK's P/E ratio is -0.43. In terms of profitability, BIAF's ROE is -3.31%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, BIAF is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
BIAF vs CNTG Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas CNTG's P/E ratio is -0.23. In terms of profitability, BIAF's ROE is -3.31%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, BIAF is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
BIAF vs APDN Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas APDN's P/E ratio is -0.10. In terms of profitability, BIAF's ROE is -3.31%, compared to APDN's ROE of -5.84%. Regarding short-term risk, BIAF is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
BIAF vs NDRA Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, NDRA has a market cap of 7.1M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while NDRA trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas NDRA's P/E ratio is -0.70. In terms of profitability, BIAF's ROE is -3.31%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, BIAF is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check NDRA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
BIAF vs BIAFW Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, BIAFW has a market cap of 5.9M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while BIAFW trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas BIAFW's P/E ratio is 0.62. In terms of profitability, BIAF's ROE is -3.31%, compared to BIAFW's ROE of -3.31%. Regarding short-term risk, BIAF is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
BIAF vs NVTA Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas NVTA's P/E ratio is -0.00. In terms of profitability, BIAF's ROE is -3.31%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, BIAF is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
BIAF vs LMDXW Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, BIAF's ROE is -3.31%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, BIAF is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
BIAF vs LMDX Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas LMDX's P/E ratio is -0.01. In terms of profitability, BIAF's ROE is -3.31%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, BIAF is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check LMDX's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
BIAF vs ADVB Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, ADVB has a market cap of 3.8M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while ADVB trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas ADVB's P/E ratio is -21.09. In terms of profitability, BIAF's ROE is -3.31%, compared to ADVB's ROE of +0.79%. Regarding short-term risk, BIAF is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check ADVB's competition here
DermTech, Inc. (NASDAQ: DMTK)
BIAF vs DMTK Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas DMTK's P/E ratio is -0.04. In terms of profitability, BIAF's ROE is -3.31%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, BIAF is more volatile compared to DMTK. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
BIAF vs NOTV Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas NOTV's P/E ratio is -0.03. In terms of profitability, BIAF's ROE is -3.31%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, BIAF is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
BIAF vs SQL Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas SQL's P/E ratio is -0.40. In terms of profitability, BIAF's ROE is -3.31%, compared to SQL's ROE of -30.46%. Regarding short-term risk, BIAF is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
BIAF vs AWH Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas AWH's P/E ratio is -0.09. In terms of profitability, BIAF's ROE is -3.31%, compared to AWH's ROE of +1.62%. Regarding short-term risk, BIAF is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
BIAF vs ISPC Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, ISPC has a market cap of 1.8M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while ISPC trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas ISPC's P/E ratio is -0.02. In terms of profitability, BIAF's ROE is -3.31%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, BIAF is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
BIAF vs HTGM Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas HTGM's P/E ratio is -0.03. In terms of profitability, BIAF's ROE is -3.31%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, BIAF is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
BIAF vs BIOC Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas BIOC's P/E ratio is -0.01. In terms of profitability, BIAF's ROE is -3.31%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, BIAF is more volatile compared to BIOC. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
BIAF vs SQLLW Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, BIAF's ROE is -3.31%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, BIAF is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
BIAF vs WGSWW Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, BIAF's ROE is -3.31%, compared to WGSWW's ROE of -0.42%. Regarding short-term risk, BIAF is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check WGSWW's competition here
Danaher Corporation (NYSE: DHR-PA)
BIAF vs DHR-PA Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, BIAF's ROE is -3.31%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, BIAF is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check DHR-PA's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
BIAF vs MEUSW Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas MEUSW's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -3.31%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, BIAF is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check MEUSW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
BIAF vs BNGOW Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas BNGOW's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -3.31%, compared to BNGOW's ROE of -0.85%. Regarding short-term risk, BIAF is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
BIAF vs CHEKZ Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -3.31%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, BIAF is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
BIAF vs OCDX Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas OCDX's P/E ratio is -42.28. In terms of profitability, BIAF's ROE is -3.31%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, BIAF is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check OCDX's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
BIAF vs NDRAW Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas NDRAW's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -3.31%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, BIAF is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check NDRAW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
BIAF vs PRXL Comparison November 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 15.2M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, BIAF is priced at $2.42 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.28, whereas PRXL's P/E ratio is 42.97. In terms of profitability, BIAF's ROE is -3.31%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, BIAF is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check PRXL's competition here